2,025.00
+1.86%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lupin
Its shares trade on NSE under the ticker LUPIN.NS. It has been listed since 30 November 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹279.58bn and net income of ₹53.33bn. At that date it held total assets of ₹383.65bn and shareholders' equity of ₹224.48bn.
Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the United States, India, South Africa, and across the Asia Pacific, Latin America, and others. The company offers vitamins, minerals, supplements and neurological products. The company has presence in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments. Its complex generics portfolio includes Filgrastim, Peg-Filgrastim, Etanercept and Albuterol, and others. Its biosimilar products include Filgrastim, Peg-Filgrastim and Etanercept. Its specialty products consist of Solosec and NaMuscla. Its over-the-counter products include Softovac, Lupizyme, Aptivate, Lupisafe, Be One and V-Bath, and others. The company supplies APIs for anti-retroviral, anti-malarial and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Nov 1994
- Employees
- 19,789
- Website
- lupin.com ↗
Leadership
Pay as last reported
- Mrs. Manju GuptaNon-Executive Chairman of the Board, since 2011₹8.9m
- Ms. Vinita GuptaChief Executive Officer, Executive Director₹235.6m
- Mr. Ramesh SwaminathanExecutive Director, Global Chief Financial Officer, Chief Risk Officer and Head of API Plus SBU, since 2007₹81.7m
- Mr. Rajendra ChunodkarPresident - Manufacturing Operations
- Dr. Fabrice EgrosPresident - Corporate Development and Growth Markets, since 2021
- Mr. Spiro GavarisPresident - U.S. Generics
- Mr. Naresh GuptaPresident - API Plus and Global TB₹14.4m
- Mr. Claus JepsenPresident - Global Specialty
- Dr. Rajender KambojPresident - Novel Drug Discovery and Development
- Dr. Cyrus KarkariaPresident - Biotechnology
- Mr. Sunil MakhariaPresident - Finance, since 2020
- Dr. Sofia MumtazPresident - Legal, Canada and APAC, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 77
- Environment
- 72
- Social
- 92
- Governance
- 68
- Direct emissions (scope 1)
- 86,345 t
- Energy emissions (scope 2)
- 306,503 t
- Value chain emissions (scope 3)
- 1,119,125 t
- Women in the workforce
- 9%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong brand recognition: Lupin Ltd has established a strong brand presence in the pharmaceutical industry, known for its quality products and innovation.
- Diversified product portfolio: The company offers a wide range of pharmaceutical products across various therapeutic areas, reducing dependency on any single product.
- Global presence: Lupin Ltd has a strong international presence, with operations in several countries, allowing it to tap into diverse markets and customer segments.
Weaknesses
- Dependency on few key markets: While Lupin Ltd has global operations, it heavily relies on a few key markets for significant revenue, which poses a risk in case of market fluctuations or regulatory challenges in those regions.
- Limited pipeline of new drugs: The company's pipeline of new drugs under development is relatively limited, which could impact its ability to maintain a competitive edge and drive future growth.
- Increasing competition: Lupin Ltd faces intense competition from other pharmaceutical companies, both domestic and international, which may impact its market share and pricing power.
Opportunities
- Rising demand for generic drugs: The increasing preference for affordable healthcare and patent expirations in the pharmaceutical industry present an opportunity for Lupin Ltd to expand its generic drug offerings.
- Emerging markets: Developing economies are experiencing a surge in healthcare spending, providing Lupin Ltd with growth opportunities in untapped markets.
- Innovation and research: Investing in research and development capabilities can help Lupin Ltd develop new drugs and therapies, driving future growth and differentiation.
Threats
- Stringent regulatory environment: Compliance with evolving regulations and increasing scrutiny in the pharmaceutical industry poses a threat to Lupin Ltd's operations and profitability.
- Patent expirations: The expiration of patents for key drugs may lead to increased competition from generic drug manufacturers, resulting in reduced market share and lower profitability.
- Currency exchange risks: As a global company, Lupin Ltd is exposed to currency exchange rate fluctuations, which can impact its financial performance and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.